Rapid Medical

Rapid Medical operates as a medical device company focused on developing and commercializing neurovascular solutions for treating ischemic and hemorrhagic strokes. Founded in 2008 by the father-and-son team of Dr. Shimon Eckhouse and Ronen Eckhouse, the company is headquartered in Yokneam, Israel. Ronen Eckhouse, the CEO, leverages a background in electrical engineering and an MBA, including previous roles at Mellanox Technologies and Amazon, to lead the company's strategic direction. The company’s business model revolves around the design, manufacturing, and sale of its specialized medical devices to hospitals and neuro-interventionalists. Revenue is generated through the sale of these products, supported by a global commercial growth strategy funded by significant investment rounds, including a $50 million Series D financing in 2021.

The company's core market is the neurovascular intervention space, addressing conditions that affect millions globally each year. Its client base consists of healthcare providers performing endovascular treatments. The company has established a direct sales presence in the Americas and international markets, with offices in the US and Germany, and also utilizes strategic partnerships, such as an exclusive agreement with MicroPort NeuroTech for commercial rights in the Greater China region.

Rapid Medical's product portfolio is built on a proprietary braiding technology platform that allows for the creation of remotely adjustable and fully visible interventional tools. A flagship product, the TIGERTRIEVER, is a stent retriever for mechanical thrombectomy in ischemic stroke patients. Unlike conventional self-expanding devices, the TIGERTRIEVER's diameter can be actively controlled by the physician during the procedure, which is intended to allow for tailored clot retrieval and enhanced vessel protection. The TIGERTRIEVER family includes various sizes, such as the TIGERTRIEVER 13, designed specifically for smaller and more distant blood vessels that were previously difficult to treat. Another key product is the COMANECI, a controllable aneurysm neck-bridging device used in hemorrhagic stroke treatment. These devices have received regulatory approvals in major markets, including CE Marks in Europe and FDA clearance in the US, enabling their use in clinical practice.

Keywords: neurovascular devices, ischemic stroke, hemorrhagic stroke, thrombectomy, stent retriever, endovascular treatment, TIGERTRIEVER, COMANECI, medical devices, clot retrieval, aneurysm treatment, neuro-interventional, minimally invasive, adjustable medical devices, stroke care, brain clot, revascularization, vascular intervention, interventional neurology, medtech